Terms: = Breast cancer AND LCK, YT16, 3932, P06239, ENSG00000182866, p56lck, pp58lck
45 results:
1. Coexistent ARID1A-PIK3CA mutations are associated with immune-related pathways in luminal breast cancer.
Anabel Sinberger L; Zahavi T; Sonnenblick A; Salmon-Divon M
Sci Rep; 2023 Nov; 13(1):20911. PubMed ID: 38017109
[TBL] [Abstract] [Full Text] [Related]
2. Identification of breast cancer lck Proto-Oncogene as a Master Regulator of TNBC Neutrophil Enrichment and Polarization.
Al Qutami F; Al Halabi W; Hachim MY
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686072
[TBL] [Abstract] [Full Text] [Related]
3. Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients.
Wang WQ; Zhang L; Yang F; Zhou HH; Zhang W; Zou Y; Liu R
Biomed Pharmacother; 2022 Nov; 155():113787. PubMed ID: 36271565
[TBL] [Abstract] [Full Text] [Related]
4. CD55 in cancer: Complementing functions in a non-canonical manner.
Bharti R; Dey G; Lin F; Lathia J; Reizes O
Cancer Lett; 2022 Dec; 551():215935. PubMed ID: 36216147
[TBL] [Abstract] [Full Text] [Related]
5. Targeting hypoxia regulated sodium driven bicarbonate transporters reduces triple negative breast cancer metastasis.
Carroll CP; Bolland H; Vancauwenberghe E; Collier P; Ritchie AA; Clarke PA; Grabowska AM; Harris AL; McIntyre A
Neoplasia; 2022 Mar; 25():41-52. PubMed ID: 35150959
[TBL] [Abstract] [Full Text] [Related]
6. Association of Genetic Ancestry and Molecular Signatures with cancer Survival Disparities: A Pan-cancer Analysis.
Lee KK; Rishishwar L; Ban D; Nagar SD; Mariño-Ramírez L; McDonald JF; Jordan IK
Cancer Res; 2022 Apr; 82(7):1222-1233. PubMed ID: 35064017
[TBL] [Abstract] [Full Text] [Related]
7. A Machine Learning Model to Predict the Triple Negative breast cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract] [Full Text] [Related]
8. Integrated Molecular and Immune Phenotype of HER2-Positive breast cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis.
Pizzamiglio S; Ciniselli CM; Triulzi T; Gargiuli C; De Cecco L; de Azambuja E; Fumagalli D; Sotiriou C; Harbeck N; Izquierdo M; Nuciforo P; Huober J; Cappelletti V; Cinieri S; Piccart M; Daidone MG; Pruneri G; Colombo MP; Tagliabue E; Verderio P; Di Cosimo S
Clin Cancer Res; 2021 Dec; 27(23):6307-6313. PubMed ID: 34548320
[TBL] [Abstract] [Full Text] [Related]
9. CD151 enrichment in exosomes of luminal androgen receptor breast cancer cell line contributes to cell invasion.
Li D; Lai W; Wang Q; Xiang Z; Nan X; Yang X; Fang Q
Biochimie; 2021 Oct; 189():65-75. PubMed ID: 34157361
[TBL] [Abstract] [Full Text] [Related]
10. Biomechanical regulation of breast cancer metastasis and progression.
Spencer A; Sligar AD; Chavarria D; Lee J; Choksi D; Patil NP; Lee H; Veith AP; Riley WJ; Desai S; Abbaspour A; Singeetham R; Baker AB
Sci Rep; 2021 May; 11(1):9838. PubMed ID: 33972619
[TBL] [Abstract] [Full Text] [Related]
11. Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer.
Tahiri A; Tekpli X; Satheesh SV; DeWijn R; Lüders T; Bukholm IR; Hurtado A; Geisler J; Kristensen VN
Breast Cancer Res Treat; 2020 Oct; 183(3):585-598. PubMed ID: 32710281
[TBL] [Abstract] [Full Text] [Related]
12. Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced breast cancer.
Katayama MLH; Vieira RADC; Andrade VP; Roela RA; Lima LGCA; Kerr LM; Campos AP; Pereira CAB; Serio PAMP; Encinas G; Maistro S; Petroni MAL; Brentani MM; Folgueira MAAK
Cells; 2019 Dec; 8(12):. PubMed ID: 31817155
[TBL] [Abstract] [Full Text] [Related]
13. Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.
Bai F; Jin Y; Zhang P; Chen H; Fu Y; Zhang M; Weng Z; Wu K
Aging (Albany NY); 2019 Nov; 11(21):9328-9347. PubMed ID: 31715586
[TBL] [Abstract] [Full Text] [Related]
14. Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase.
Berndt S; Gurevich VV; Iverson TM
PLoS One; 2019; 14(4):e0215140. PubMed ID: 30969999
[TBL] [Abstract] [Full Text] [Related]
15. TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10.
Tan P; Ye Y; He L; Xie J; Jing J; Ma G; Pan H; Han L; Han W; Zhou Y
PLoS Biol; 2018 Nov; 16(11):e3000051. PubMed ID: 30408026
[TBL] [Abstract] [Full Text] [Related]
16. Assessment of the implant geometry in fractionated interstitial HDR breast brachytherapy using an electromagnetic tracking system.
Kellermeier M; Fietkau R; Strnad V; Bert C
Brachytherapy; 2018; 17(1):94-102. PubMed ID: 29146103
[TBL] [Abstract] [Full Text] [Related]
17. Impact of an In Situ Component on Outcome After In-breast Tumor Recurrence in Patients Treated with breast-Conserving Therapy.
Laird J; Lok B; Siu C; Cahlon O; Khan AJ; McCormick B; Powell SN; Cody H; Wen HY; Ho A; Braunstein LZ
Ann Surg Oncol; 2018 Jan; 25(1):154-163. PubMed ID: 29094250
[TBL] [Abstract] [Full Text] [Related]
18. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.
Iglesia MD; Parker JS; Hoadley KA; Serody JS; Perou CM; Vincent BG
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27335052
[TBL] [Abstract] [Full Text] [Related]
19. Association Between BRCA Status and P53 Status in breast cancer: A Meta-Analysis.
Peng L; Xu T; Long T; Zuo H
Med Sci Monit; 2016 Jun; 22():1939-45. PubMed ID: 27272763
[TBL] [Abstract] [Full Text] [Related]
20. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid cancer.
Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
[TBL] [Abstract] [Full Text] [Related]
[Next]
